Harnessing human plasmacytoid dendritic cells as professional APCs

Jurjen Tel · Anne M. van der Leun · Carl G. Figdor · Ruurd Torensma · I. Jolanda M. de Vries

Abstract The plasmacytoid dendritic cell (pDC) constitutes a unique DC subset that links the innate and adaptive arm of the immune system. Whereas the unique capability of pDCs to produce large amounts of type I IFNs in response to pathogen recognition is generally accepted, their antigen-presenting function is often neglected since most studies on antigen presentation are aimed at other DC subsets. Recently, pDCs were demonstrated capable to present antigen leading to protective tumor immunity. In this review, we discuss how pDCs could be exploited in the fight against cancer by analyzing their capacity to capture, process and (cross-) present antigen.

Keywords PIVAC 11 · Plasmacytoid dendritic cells · Antigen-uptake receptors · Antigen presentation · Targeting

Introduction The human immune system constitutes of a wide variety of cell types to maintain immune homeostasis. In this system, professional antigen-presenting cells (APCs) control the tight balance between tolerance and immunity. All professional APCs exploit an efficient antigen-uptake machinery and long-lived MHC class II-peptide complexes on the cell surface. Dendritic cells (DCs) represent a family of professional APCs that are derived from hematopoietic precursors and have the capacity to induce antigen-specific T-cell responses. Efficient priming is dependent on full maturation of DCs, which is evoked by the recognition of specific pathogen-associated molecular patterns by their distinct pathogen recognition receptors (PPRs). Some of the best characterized PPRs expressed by DCs are the toll-like receptors (TLRs) that are able to bind different pathogen structures like LPS, lipoprotein structures, DNA or single- and double-stranded RNA motifs, thereby initiating a signaling cascade leading to upregulated expression of MHC and co-stimulatory molecules on the cell surface, presentation of antigens and enhanced cytokine production [1, 2]. After infection or inflammation, this maturation process enables DCs to migrate to the lymph nodes and presents encountered antigens to naïve T cells.

The DC family is very heterogeneous and consists of different DC subsets each with specific functional characteristics. In general, two different DC subtypes can be distinguished, for example, myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). These distinct subsets express various surface receptors and PPRs, which determine their specialized functions (Table 1) [3]. The mDC subset can be identified and subdivided in three different subtypes by the expression of CD11c in combination with their unique surface molecules CD1c (BDCA1), CD141 (BDCA3) and...
### Table 1 Phenotypical and functional characteristics of blood DC subsets [3, 6, 45, 62, 82–84]

| Phenotype | pDCs | mDCs |
|-----------|------|------|
| **Steady state** | **Activated** | **Steady state** | **Activated** | **Steady state** | **Activated** | **Steady state** | **Activated** |
| **Phenotype** | | | | | | | |
| CD4 | ++ | ++ | + | ++ | + | ++ | + |
| CD11c | - | - | ++ | ++ | ++ | ++ | ++ |
| CD40 | +/- | +++ | +/- | +++ | +/- | +++ | +/- |
| CD80 | - | ++ | - | ++ | - | ++ | - |
| CD83 | - | + | - | + | - | + | - |
| CD86 | + | +++ | + | +++ | + | +++ | + |
| HLA-DR | ++ | +++ | ++ | +++ | ++ | +++ | ++ |
| HLA-ABC | +/- | ++ | + | ++ | + | ++ | + |
| CCR7 | - | ++ | - | ++ | - | ++ | - |
| TLR-1 | + | + | + | + | + | + | + |
| TLR-2 | - | ++ | ++ | + | ++ | + |
| TLR-3 | - | ++ | ++ | - | ++ | + |
| TLR-4 | - | + | + | + | + |
| TLR-5 | - | + | +/- | + | + |
| TLR-6 | +/- | + | + | + | + |
| TLR-7 | ++ | +/- | +/- | + | + |
| TLR-8 | - | + | + | + | + |
| TLR-9 | +++ | - | - | - |
| TLR-10 | + | + | + | + |
| DEC-205 | ++ | ++ | +++ | + |
| DCIR | + | + | - | + |
| BDCA-2 | ++ | - | - | - |
| CLEC9a | - | - | + | - |
| Fc receptors | | | | | | | |
| FcεRI | +/- | - | - | - |
| FcεRI | + | + | - | - |
| FcγRI | - | - | - | + |
| FcγRIIa | + | + | + | + |
| FcγRIIb | - | + | + | + |
| FcγRIII | - | + | - | +/- |
| **Upon activation** | | | | | | | |
| Cytokine secretion | | | | | | | |
| IFNα | +++ | - | - | - |
| IFNβ | +++ | + | + | + |
| IFNγ | ++ | - | - | - |
| IFNλ | + | + | + | + |
| IL-1β | + | + | + | + |
| IL-6 | ++ | ++ | ++ | +++ |
| IL-8 | +++ | +++ | +++ | +++ |
| IL-12 | - | + | + | + |
| TNFα | +++ | +++ | +++ | +++ |
| Migration | | | | | | | |
| Ag (cross-) presentation | | | | | | | |
| CD4 | + | + | + | + |
| Th1 | + | + | + | + |
| CD8 | + | + | + | +/- |

*After activation, pDC-derived type I IFNs and mDC-derived IL-12 are involved in the differentiation of Th1 cells.*
CD16 [4]. Classically, mDCs reside in peripheral tissues in an immature state and migrate to lymph nodes after their maturation where they produce IL-12 and activate T cells [5, 6]. pDCs are an extraordinary subset that differs from the other DC subsets by a specific feature: the capacity to produce large amounts of type I IFNs in response to viral or bacterial stimuli, pDCs employ TLR7 and TLR9, located in intracellular endosomes and lysosomes, to recognize single-stranded viral RNA or unmethylated CpG DNA motifs, respectively [7, 8]. Through the secretion of high levels of type I IFNs, pDCs communicate with other immune cells, for example, they stimulate mDCs to enhance T-cell activation and activate natural killer cells and B cells. In this way, pDCs link the innate and adaptive arm of the immune response [2, 9]. In contrast to mDCs, pDCs are hardly found in peripheral tissues under steady-state conditions. Instead, pDCs circulate through the body after entering the bloodstream and reach secondary lymphoid organs via high endothelial venules, while most other DC subsets enter secondary lymphoid organs via the lymph vessels. Following inflammation, pDCs leave the bloodstream and accumulate in the infectious site to take up antigens, followed by migration to lymph nodes to present the encountered antigens [10]. The unique capability of pDCs to produce large amounts of type I IFNs in response to pathogen recognition is well accepted. However, the position of pDCs as professional APCs has long been dictated by the view that pDCs are inferior to mDCs as it comes to antigen presentation. In this review, we discuss how pDCs could be exploited in the fight against cancer by analyzing their capacity to capture, process and (cross-) present antigen.

**pDCs induce antitumor immune responses leading to protective immunity**

Most DC-based immunotherapy has been performed with monocyte-derived DCs that were generated ex vivo [11–13]. Although clinical outcomes were observed in a fraction of patients treated with DCs [12–17], it has been postulated that moDCs might be less effective than naturally occurring DC subsets. pDCs comprise one of these natural DC subsets circulating in the blood and are potential candidates for DC-based antitumor immunotherapy as detailed below.

The observation that human pDCs were able to induce T-cell responses in vitro confirmed results observed in mice where CpG or influenza virus matured pDCs-induced ovalalbumin (OVA)-specific CD4+ and CD8+ T-cell responses [18–22]. While CpG-matured pDCs induced CD8+ T-cell responses against endogenous antigens, no T-cell responses were observed against exogenous OVA antigen [23]. This discrepancy could in part be attributed to the fact that in some studies, pDCs were pulsed with the entire OVA protein, while others used OVA fragments. In other studies with exogenous antigens like influenza A or HSV, pDCs also induced CD4+ and CD8+ T-cell responses, again indicating their capacity to present antigens and stimulate T cells [24–26]. Notwithstanding these results, pDCs were less effective in CD4+ priming when compared to mDCs when both are stimulated with TLR agonists, like LPS [19]. This might be explained by the fact that mDCs express high levels of TLR4 where pDCs do not. Salio et al. [23] proposed that high numbers of peptide-pulsed pDCs are equally efficient as peptide-pulsed mDCs in priming of CD8+ T cells. This notion is supported by the finding that murine pDCs exposed to influenza virus induced the generation of memory CD8+ T cells as well as effector CD8+ T cells upon rechallenge with the virus, leading to protective immunity [20]. Further evidence that pDCs can induce protective immunity comes from studies where mice were vaccinated with CpG-matured tumor peptide-pulsed pDCs or pulsed by a *Leishmania major* (L. major) lysate. Mice vaccinated with tumor peptide-loaded pDCs gained antitumor immunity and were protected upon tumor challenge, whereas nonvaccinated animals showed unhampered tumor growth [23]. This indicates that mature pDCs can effectively generate protective immunity [27]. Together, these data emphasize the potential of pDCs as type I IFN-secreting professional APCs.

**Antigen cross-presentation by pDCs**

A potent immune response requires both CD4+ T-cell and effector CD8+ responses. To this end, the capacity of DCs to cross-present antigen is absolutely essential. In contrast to the well-defined capacity of human CD141+ mDCs and mouse CD8α+ mDCs to cross-present antigens [28–31], controversy exists about ability of pDCs to cross-present. Although in some studies murine pDCs fail to induce functional CD8+ T cells [18, 32], human pDCs appear to be competent in processing exogenous antigens to be presented in MHC class I molecules [33–35] (Fig. 1). Exogenous antigens captured by pDCs might end up in MHC class I through distinct routes; via an endosome-to-cytosol pathway or via a cytosol-independent pathway [36–38]. Di Pucchio et al. [35] showed that a functional proteasome is not necessary for pDCs to present captured viral antigens in MHC class I molecules, indicating that pDCs have the capacity to process and load captured antigens directly onto MHC class I molecules in endosomal compartments. This is in contrast with findings showing that exogenous antigens need to be transported from endosomal vesicles into the cytosol, become processed by the proteasome and
subsequently loaded on MHC class I molecules, similar to endogenous antigens [39, 40]. Other studies showed that pDCs can cross-present antigens directly after stimulation with viral pathogens with comparable efficacy as mDC subsets. It has been reported that pDCs have larger amounts of MHC class I molecules stored in endosomes when compared to other DC subsets and can therefore rapidly transport these MHC class I molecules to the plasma membrane [35]. Taken together, studies performed with human pDCs suggest that an effective cross-presentation machinery is present. Human pDCs can be regarded as professional APCs and should therefore be considered for immunotherapy.

**Antigen uptake by pDC**

Two main strategies are exploited in DC-based cancer immunotherapy: (1) isolation and ex vivo stimulation of autologous DCs and (2) via direct targeting of DCs in vivo. Until now, clinical trials have primarily focused on the generation, stimulation and manipulation of DCs ex vivo.

To compose a potent vaccine, the antigenic cargo needs to be efficiently and specifically delivered, avoiding inappropriate release of vaccine content. Furthermore, to explore the most potent mechanism to stimulate immature pDCs with antigens in vivo, it is important to dissect the antigen-uptake and stimulation mechanisms of pDCs. Immature DCs are able to take up various types of exogenous antigens through macropinocytosis, phagocytosis or receptor-mediated endocytosis [41]. Macropinocytosis refers to a process that mediates nonspecific capture of soluble antigens, without the involvement of receptors. While phagocytosis comprises receptor-mediated engulfment of larger antigenic particles or pathogens, receptor-mediated endocytosis is considered the most specific and efficient mechanism to capture antigens [41].

**Phagocytosis and pinocytosis**

Like reported for immature mDCs, immature pDCs can phagocytose viral pathogens such as cytomegalovirus, HIV-I and influenza A resulting in priming naïve CD8^+^ T cells [42, 43]. In contrast to their ability to engulf viruses,
there has been some controversy whether or not pDCs are involved in the uptake of bacteria. Some studies demonstrate that pDCs were able to take up and get activated by bacteria like S. pyogenes and S. aureus [43, 44], while Piccioli et al. [45] showed that pDCs were not able to phagocytose nor get activated by S. aureus. Other studies demonstrated that pDCs hardly take up apoptotic cells compared with mDCs [46, 47], while Hoeffel et al. [39] showed that pDCs are capable of taking up apoptotic cell fragments. These opposing results suggest that pDCs are endowed with specific PRRs that are involved in the specific recognition of particular bacteria [43]. Other studies have focused on the mechanisms for taking up soluble antigens including KLH and OVA. Immature pDCs are likely capable of taking up soluble antigens, but less efficient than mDCs [18, 21, 48]. This difference in effectiveness could be caused by the lower macropinocytosis activity of pDCs compared with mDCs [49].

Although pDCs are considered to be ineffective in engulfing particulate antigens like bacteria and apoptotic cells, we previously demonstrated that human pDCs induced immune responses after internalizing particulate matter [50]. Stimulating pDCs with polylactic-co-glycolic acid (PLGA) microparticles packed with antigens and TLR agonists resulted in the activation of antigen-specific CD4+ T cells [50]. Thus, although pDCs are less efficient than mDCs, they can phagocytose and process particles, which simultaneously release TLR agonists and antigens. As a consequence, pDCs mature and MHC class II molecules are loaded with antigens. Interestingly, although human pDCs were found to be less efficient when compared to mDCs in taking up particulate compounds, both cell types were fully matured. These findings suggest that pDCs might even be more competent in handling engulfed materials than mDCs.

Receptor-mediated endocytosis

Next to the ability to take up encountered pathogens and antigens by phagocytosis, pDCs are also known to express a broad repertoire of antigen-uptake receptors on their cell surface (Table 1; Fig. 1). This large repertoire facilitates the uptake of encountered pathogens and antigens via receptor-mediated endocytosis, resulting in more efficient antigen uptake than via phagocytosis.

**Fc receptors**

One of the best defined receptor families relevant for the uptake of microbial pathogens is the Fc receptor family. They mediate endocytosis and presentation of antigens by capturing immune complexes. Fc receptors do not mediate uptake of soluble antigens, but antigens forming immune complexes with antibodies [51, 52]. The human FcγR family consists of the activating receptors FcγRI (CD64), FcγRIIIa/c (CD32a/c) and FcγRIIa/b(CD16), and the inhibitory receptor FcγRIIb (CD32b) [53]. pDCs express FcγRIIa [54, 55], FcζR (unpublished observation) and FcεR [56], but not FcγRI and FcγRIIa/b (Table 1). FcγRIIa-mediated internalization stimulates the redistribution of MHC class II molecules from lysosomal vesicles to the plasma membrane, facilitating presentation of antigen-IgG complexes captured by FcγRIIa in both MHC class I and MHC class II molecules [54, 57]. The FcγRIIa surface expression levels are similar for immature and mature pDCs. However, triggering of TLRs results in decreased endocytosis via FcγRIIa, indicating impaired internalization after pDC maturation. This might prevent the uptake of antigens, which are not associated with TLR activation, to be captured after maturation [55]. Whether FcζR and FcεR expressed by human pDCs are involved in antigen uptake and presentation remains to be established. Triggering FcζR or FcεR does not affect the expression of surface receptors involved in providing co-stimulatory signals during T-cell activation [54]. However, these receptors differ in their ability to modulate the secretion of type I IFN by pDCs in response to TLR ligation. Although both receptors employ an ITAM for downstream signaling, FcζR triggering strongly impairs TLR9-induced IFNα secretion [56], while FcγRIIa triggering leaves TLR9-induced IFNα secretion unaffected [55].

**C-type lectin receptors on pDCs**

Another endocytic receptor family expressed on the immature pDCs are the C-type lectin receptors (CLRs) (Fig. 1). CLRs recognize carbohydrate moieties leading to internalization, the “C” indicating Ca²⁺ dependence of carbohydrate binding [58]. BDCA-2 is a type II CLR exclusively expressed by immature pDCs and used as a marker to distinguish immature pDCs from mDCs and other immune cells [59]. BDCA-2 is shown to capture antigens decorated with carbohydrates, leading to presentation of the captured antigen on MHC class II molecules. However, triggering BDCA-2 impairs TLR9-mediated type I IFN secretion by pDCs, thereby attenuating the induction of innate immune responses [60]. Furthermore, BDCA-2 expression is reduced by TLR7 and TLR9 signaling, indicating that the endocytic function of BDCA-2 is primarily important in immature pDCs [61]. In addition to BDCA-2, pDCs also express the more broadly expressed CLRs DEC-205 and DCIR [62, 63]. Triggering DEC-205 and DCIR both inhibit TLR9-mediated type I IFN secretion by pDCs, but to a lesser extent than triggering through BDCA-2. Moreover, neither DEC-205 nor DCIR affect the expression of co-stimulatory molecules on the plasma membrane.
followed by the induction of CD4+
processing and presentation in MHC class II molecules, uptake of antigens by DEC-205 and DCIR leads to antigen
nalize antigens [62]. Like antigen capture by other CLRs, downregulated upon TLR-induced activation, DEC-205
of most endocytic receptors on pDCs, such as DCIR, is specific CD8
72]. In mice, Siglec-H is involved in antigen cross-
expansion of both antigen-specific CD4
363]. Interestingly, under same conditions targeting of DEC-
205 on pDCs induced highly similar T-cell responses [62,
63]. Interestingly, under same conditions targeting of DEC-205 on pDCs induced highly similar T-cell responses compared to responses induced by CD1c+ mDCs and moDCs [62]. These findings reveal that pDCs, although generally considered inferior, are as efficient and professional as other mDCs, generally accepted as professional APC. Whether BDCA-2, DEC-205 and/or DCIR is involved in antigen cross-presentation by human pDCs remains to be elucidated. Initial observations that mDCs can cross-present antigens captured by DEC-205 and DCIR suggest that both receptors might be able to perform a similar role in pDCs as well [63, 65–67].

Targeted delivery: Which receptor to aim for?

Facilitating the targeted delivery of particulate vaccines to DCs in vivo via receptor-mediated endocytosis seems an interesting opportunity, since this mechanism allows the specific and simultaneous delivery of maturation factors and antigens. But which receptor should be selected to obtain a potent immune response when considering antigen-presenting pDCs?

Several studies identified receptors for in vivo targeting of pDCs. In mice, Siglec-H and bone marrow stromal cell antigen 2 (BST2) were identified as pDC-specific receptors that opt for interesting targets [68]. Siglec-H is an endocytic receptor and member of the Siglec receptor family. Although most Siglec family members contain an ITIM sequence, Siglec-H lacks this domain [69, 70]. Siglec-H associates with DAP-12, which in spite of having this ITAM motif, result in impaired secretion of type I IFN [71, 72]. In mice, Siglec-H is involved in antigen cross-presentation, as demonstrated by the priming of antigen-specific CD8+ T cells upon antigen uptake via Siglec-H [69]. Recently, Loschko et al. [73] underscored the potency of targeting pDCs in vivo via BST2. In their study, they reported that targeted pDCs were efficient inducers of the expansion of both antigen-specific CD4+ and CD8+ T-cell responses. Interestingly, they observed protective antitumor responses when targeting pDCs with simultaneous administration of a TLR agonist [73]. This makes Siglec-H and BST2 potent receptors for targeting murine pDCs for the induction of CD8+ T-cell responses and protective tumor immunity. Although specific for murine pDCs, human pDCs do not express Siglec-H [74]. Freshly isolated as well as activated human pDCs do express BST2 [75]. However, in man expression of BST2 is not restricted to pDCs as it is also expressed by B cells. Moreover, it is upregulated on various cells upon IFNα treatment. Therefore, other receptors expressed by pDCs might be better suited [75]. Regarding the characteristics of the different surface receptors expressed by pDCs, specifically targeting antigen to the ITAM-containing FcγRIIa seems to be a promising strategy to induce immunity, since FcγRIIa is involved in T-cell priming, and moreover triggering FcγRIIa does not negatively affect type I IFN production. One disadvantage of FcγRIIa is that it is not uniquely expressed by pDCs, meaning that pDCs cannot be specifically targeted by triggering FcγRIIa [52]. Similarly, although DEC-205 expression is largely restricted to DCs in mice, it is broadly expressed on different immune cells in man (Table 1) [76]. In this respect, DCIR is expressed by less diverse immune cell types, making this receptor more potent for specific targeting of pDCs. Nevertheless, targeting DCIR might also activate other DC types like mDCs. Combining the stimulation of both DC types unlocks an interesting approach to potentially establish a more potent vaccine, since interaction between pDCs and mDCs has been demonstrated to increase antigen-specific immune responses. Activating pDCs along with mDCs leads also to induction of innate immune responses, likely resulting in an intensified adaptive immune response. pDCs are found to stimulate and enhance the cytokine secretion and cross-presentation of antigens leading to CD8+ T-cell priming by mDCs and induction of an antiviral immune response by moDCs [77–79]. In turn, pDCs cocultured with mDCs are capable of inducing an immune response against bacteria where they fail to respond on their own [45]. In mice, an enhanced antitumor response was found when mDCs and pDCs were cocultured during pulsing with tumor antigens [80]. Moreover, pDCs were found to cross-talk indirectly with mDCs, via activation of specific lymphocyte subsets that can interact with, and might thereby stimulate, mDCs [81]. Together, these observations strongly suggest that combining pDC activation with the activation of other DC subsets might be advantageous and result in a more powerful immune response. Triggering DCIR could potentially establish such a synergetic immune response, while triggering pDC-specific receptors, like BDCA-2, initiate a more restricted induced immune response. Moreover, triggering DCIR does not completely inhibit TLR-induced type I IFN secretion by pDC as would be caused by BDCA-2 ligation. We hypothesize that the locally secreted type I IFN is important to establish an effective immune response, since type I IFNs links innate and adaptive immune responses by cross-talk with mDCs, natural killer T cells, natural killer cells and B cells.
Alternatively, targeting CD40 could be considered, since it induces TLR-independent pDC maturation without negatively affecting type I IFN secretion. However, like FcγRIIa, BST2 and DEC-205, CD40 is expressed on many different cell types other then DCs and might therefore be less powerful for targeting pDCs.

**Conclusion**

Human pDCs seem well equipped for therapeutic strategies aimed at eliciting specific immune response and tumor eradication. Although there is still some controversy on the cross-presenting ability of pDCs, several studies demonstrate that they can cross-present antigens and effectively induce antigen-specific CD8\(^+\) T-cell responses leading to protective tumor immunity in both mice and man. Therefore, it might be interesting to directly target pDCs in vivo to simultaneously deliver TLR agonists and antigens. Based on existing literature, DCIR seems a potent target, since triggering of this receptor leads to antigen presentation by pDCs as well as other DC subsets without totally blocking the TLR-induced cytokine secretion. Furthermore, combined stimulation of pDCs and mDCs seems to induce a more potent and powerful immune response and therefore deserves more elaborate study. This knowledge will certainly help to map the way for DC-based targeting strategies that can be exploited in autoimmune and infectious diseases as well as in cancer.

**Acknowledgments** This research was supported by NWO Vidi grant 917.76.363 to JdV, by EU grants Cancerimmunotherapy (LSHC-CT-2006–518234) and DC-THERA (LSHB-CT-2004–512074), and by the NOTK foundation and the TIL foundation. CF was awarded with a NWO Spinoza prize.

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**References**

1. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune response. Nat Immunol 5(10):987–995
2. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239(1):178–196
3. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, de Vries IJ (2010) Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 59(10):1573–1582
4. Mittag D, Projetti A, Loudovaris T, Mannering SJ, Vremec D, Shortman K, Wu L, Harrison LC (2011) Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J Immunol 186(11):6207–6217
5. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A (2001) Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 31(11):3388–3393
6. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 194(6):863–869
7. Gilliet M, Cao W, Liu YJ (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8(8):594–606
8. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760
9. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303(5663):1526–1529
10. Conrad C, Meller S, Gilliet M (2009) Plasmacytoid dendritic cells in the skin: to sense or not to sense nucleic acids. Semin Immunol 21(3):101–109
11. Holzl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesch C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M (2005) Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54(7):663–670
12. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paraglik N, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93(2):243–251
13. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Kravosky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF, Bhardwaj N (1999) Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104(2):173–180
14. Lesteurhuis WJ, de Vries IJ, Schreibelt G, Lambrecht GA, Stugten EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Crockewit S, van Rossum MM, Mus R, Oyen WJ, Vagahn OC, Lucas S, Adema GJ, Punt CJ, Figdor CG (2011) Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17(15):5725–5735
15. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61(17):6451–6458
16. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesteurhuis WJ, Diepstra JH, Van Muijen GN, Strijk JP, Ruers Tj, Boerman OC, Oyen WJ, Adema GJ, Punt CJ, Figdor CG (2005) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 65(1):12–17
17. de Vries IJ, Lesteurhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Crockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9(4):5091–5100
18. Sapoznikov A, Fischer JA, Zaat T, Krauthgamer R, Dzionek A, Jung S (2007) Organ-dependent in vivopriming of naive CD4+ cells, but not CD8+ T cells by plasmacytoid dendritic cells. J Exp Med 204(8):1923–1933

19. Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G, Liu YJ, O’Garra A (2003) Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 197(1):101–109

20. Schlecht G, Garcia S, Escriou N, Freitas AA, Leclerc C, Dadaglio M, Ishido S, Stoorvogel W, Heath WR, Shortman K, Villadangos JA (2008) Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nature Immunol 9(11):1244–1252

21. Brimnes MK, Bonifaz L, Steinman RM, Moran TM (2003) Influenza virus-induced dendritic cell maturation is associated with the induction of strong T cell immunity to a coadministered, normally nonimmunogenic protein. J Exp Med 198(1):133–136

22. Salio M, Palmowski MJ, Atzberger A, Hermans IF, Cerundolo V, Brimnes MK, Bonifaz L, Steinman RM, Moran TM (2003) Flexibility of plasmacytoid dendritic cells to induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood 104(6):1808–1815

23. Young LJ, Wilson NS, Schnorrer P, Proietto A, ten Broeke T, Schlecht G, Garcia S, Escriou N, Freitas AA, Leclerc C, Dadaglio M, Ishido S, Stoorvogel W, Heath WR, Shortman K, Villadangos JA (2008) Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nature Immunol 9(11):1244–1252

24. Cella M, Facchetti F, Lanzavecchia A, Colonna M (2000) Plasmacytoid dendritic cells activated by influenza virus and CD40L drive the potent TH1 polarization. Nature Immunol 1(4):305–310

25. Remer KA, Apetrei C, Schwarz T, Linden C, Moll H (2007) Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice. Eur J Immunol 37(9):2463–2473

26. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Stent G, Reece JC, Baylis DC, Ivinson K, Paukovics G, Thomson MF, Kawamura K, Kadowaki N, Kitawaki T, Uchiyama T (2006) Mechanisms and role in immune surveillance. Immunol Rev 207:166–183

27. Dalgaard J, Beckstrom KJ, Jahnsen FL, Brinchmann JE (2005) Differential toll-like receptor ligation. J Exp Med 197(7):885–898

28. Parcina M, Wendt C, Goetz F, Zawatzky R, Zahringer U, Heeg K, Bekeredian-Ding I (2008) Staphylococcus aureus-induced plasmacytoid dendritic cell activation is based on an IgG-mediated memory response. J Immunol 181(6):3283–3288

29. Dzionek A, Belz GT, O’Keeffe M, Ohmura-Hoshino M, Mount AM, Belz GT, O’Keeffe M, Ohmura-Hoshino M, Ishido S, Stoorvogel W, Heath WR, Shortman K, Villadangos JA (2008) Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nature Immunol 9(11):1244–1252

30. Casartelli N, Schwartz O, De la Salle H, Hosmalin A, Mokanen P, Zelenay S, Nye E, Le Moine A, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, Le Moine A, Cameron PU (2002) Heterogeneity of freshly isolated human tonsil dendritic cells demonstrated by intracellular markers, phagocytosis, and membrane dye transfer. Cytometry 48(3):167–176

31. Fazekas H, Manchess O, Angel J, Molens JP, Chaperot L, Plumas J (2009) Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells. PLoS One 4(9):e7111

32. de Heer HJ, Hammad H, Soullie T, Hijdra D, Vos N, Willart MA, Hoogsteden HC, Lambrecht BN (2004) Essential role of lung dendritic cells in the business. Immunity 27(3):419–412

33. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA (2005) Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 207:145–157

34. Rock KL, Shen L (2005) Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 207:166–183

35. Dalod M, Hamilton T, Salomon R, Salazar-Mather TP, Henry SC, Hamilton JD, Biron CA (2003) Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. J Exp Med 197(7):885–898

36. Veckman V, Julkunen I (2008) Streplococcus pyogenes activates human plasmacytoid and myeloid dendritic cells. J Leukoc Biol 83(2):296–304

37. Piccoli D, Sammicheli C, Tavarnini S, Nuti S, Frigimelica E, Manetti AGO, Nuccitelli A, Aprea S, Valentini S, Borgogni E, Wack A, Valiante NM (2009) Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood 113(18):4232–4239

38. Dalgaard J, Beckstrom KJ, Jahnsen FL, Brinchmann JE (2005) Differential capability for phagocytosis of apoptotic and necrotic leukemia cells by human peripheral blood dendritic cell subsets. J Leukoc Biol 77(5):689–698

39. Stent G, Reece JC, Bayliss DC, Ivinson K, Paukovics G, Thomson MF, Cameron PU (2002) Heterogeneity of freshly isolated human tonsil dendritic cells demonstrated by intracellular markers, phagocytosis, and membrane dye transfer. Cytometry 48(3):167–176

40. Stent G, Reece JC, Bayliss DC, Ivinson K, Paukovics G, Thomson MF, Cameron PU (2002) Heterogeneity of freshly isolated human tonsil dendritic cells demonstrated by intracellular markers, phagocytosis, and membrane dye transfer. Cytometry 48(3):167–176
plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 200(1):89–98

49. Robinson SP, Patterson S, English N, Davies D, Knight SC, Reid CD (1999) Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 29(9):2769–2778

50. Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, de Vries JJ, Figdor CG (2010) Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol 184(8):4276–4283

51. Amigorena S, Bonnerot C (1999) FCe receptor signaling and trafficking: a connection for antigen processing. Immunol Rev 172:279–284

52. Fanger NA, Wardwell K, Shen L, Tedder TF, Guuye PM (1996) Type I (CD64) and type II (CD32) FC gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 157(2):541–548

53. Wof JM, Burton DR (2004) Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 4(2):89–99

54. Benitez-Ribas D, Adema GJ, Winkels G, Klasen IS, Punt CJ, Figdor CG, de Vries IJM, Figdor CG, Adema GJ (2009) DCIR is endocytosed into plasmacytoid dendritic cells. Eur J Immunol 41(4):1014–1023

55. Benitez-Ribas D, Tacken P, Punt CJA, de Vries IJM, Figdor CG, de Vries IJM, Figdor CG, Adema GJ (2008) Targeting DCIR on human plasmacytoid dendritic cells in atopic dermatitis. J Aller Clin Immunol 114(2):360–370

56. Novak N, Allan JP, Hagemann T, Jenneck C, Laffer S, Valenta R, Kocian J, Bieber T (2004) Characterization of FcγRII-mediated uptake. J Exp Med 203(7):1629–1635

57. Kuwajima S, Sato T, Ishida K, Tada H, Tezuka H, Ohteki T, Kuwajima S, Sato T, Ishida K, Tada H, Tezuka H, Ohteki T, et al. (2004) Regulation of TLR7/9 responses in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trend Immunol 27(6):255–260

58. Loschko J, Schlitzer A, Dudziak D, Drexler I, Sandholzer N, Loschko J, Schlitzer A, Dudziak D, Drexler I, Sandholzer N, et al. (2004) TLR9 function in plasmacytoid dendritic cells. Cancer Res 64(5):1726–1733

59. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196(12):1627–1638

60. Geijtenbeek TBH, Gringhuis SI (2009) Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 9(7):465–479

61. Kato M, McDonald KJ, Khan S, Ross IL, Vuckovic S, Chen K, Kato M, McDonald KJ, Khan S, Ross IL, Vuckovic S, Chen K, et al. (2009) Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 177(5):3260–3265

62. Blasius AL, Giurisato E, Celli M, Schreiber RD, Shaw AS, Blasius AL, Giurisato E, Celli M, Schreiber RD, Shaw AS, et al. (2006) Cross-talk between human dendritic cell subsets influences expression of RNA sensors and inducers of innate immune activation. Nat Immunol 7(7):740–746

63. Blasius AL, Colonna M (2006) Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 107(9):3600–3608

64. Crocker PR (2005) Siglecs in innate immunity. Curr Opin Pharmacol 5(4):431–437

65. Blasius AL, Celli M, Maldonado J, Takai T, Colonna M (2006) Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DA512. Blood 107(6):2474–2476

66. Blasius AL, Colonna M (2006) Sampling and signaling in plasmacytoid dendritic cells: the potential roles of Siglec-H. Trend Immunol 27(6):255–260

67. Cao W, Bover L, Cho M, Wen X, Hanabuchi S, Bao M, Rosen DB, Wang YH, Shaw JL, Du Q, Li C, Arai N, Yao Z, Lanier LL, Cao W, Bover L, Cho M, Wen X, Hanabuchi S, Bao M, Rosen DB, Wang YH, Shaw JL, Du Q, Li C, Arai N, Yao Z, Lanier LL, et al. (2009) Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 induces protective T cell-mediated immunity. J Immunol 186(12):6718–6725

68. Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J, Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J, et al. (2009) Plasmacytoid dendritic cells synergize with myeloid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 206(7):1603–1614

69. Palucka AK, Zurawski G, Banchereau J (2010) Cross-priming of dendritic cells. Eur J Immunol 40(7):1960–1970

70. Kato M, McDonald KJ, Khan S, Ross IL, Vuckovic S, Chen K, Kato M, McDonald KJ, Khan S, Ross IL, Vuckovic S, Chen K, et al. (2009) Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and IIT7 receptor interaction. J Exp Med 206(7):1603–1614

71. Kondo M, MacDonald KP, Hart D (2006) Expression of human DEC-205 (CD205) multielectrin receptor on leukocytes. Int Immunol 18(6):857–869

72. Kuwajima S, Sato T, Ishida K, Tada H, Tezuka H, Ohteki T, Kuwajima S, Sato T, Ishida K, Tada H, Tezuka H, Ohteki T, et al. (2004) Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced innate activation. Nat Immunol 7(7):740–746

73. Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenars J, Wassink M, Boon L, Ruers TJ, Figdor CG, Schoenberger SP, Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenars J, Wassink M, Boon L, Ruers TJ, Figdor CG, Schoenberger SP, et al. (2009) Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res 70(20):6428–6437

74. Kramer M, Schulte BM, Eleved-Trancikova D, van Hout-Kuijer M, Toonen LWI, Tei J, de Vries IJM, van Kuppeveld FJM, Kramer M, Schulte BM, Eleved-Trancikova D, van Hout-Kuijer M, Toonen LWI, Tei J, de Vries IJM, van Kuppeveld FJM, et al. (2010) Cross-talk between human dendritic cell subsets influences expression of RNA sensors and inhibits picornavirus infection. J Innate Immun 2(4):360–370

75. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G (2007) Plasmacytoid dendritic cells synergize with myeloid dendritic cells in
the induction of antigen-specific antitumor immune responses. J Immunol 178(3):1534–1541
81. Montoya CJ, Jie HB, Al-Harthi L, Mulder C, Patino PJ, Rugeles MT, Krieg AM, Landay AL, Wilson SB (2006) Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. J Immunol 177(2):1028–1039
82. Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJM (2012) The C type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood. doi: 10.1182/blood-2011-08-373944
83. MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN (2002) Characterization of human blood dendritic cell subsets. Blood 100(13):4512–4520
84. Piccioli D, Tavarini S, Borgogni E, Steri V, Nuti S, Sammicheli C, Bardelli M, Montagna D, Locatelli F, Wack A (2007) Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 109(12):5371–5379